Dual glucagon‐like peptide‐1/glucagon receptor (GLP‐1/GCGR) agonists represent a novel obesity treatment class, but existing meta‐analyses often conflate them with GIP‐containing agents (tirzepatide, retatrutide) or restrict analysis to one or two drugs, leaving class‐specific efficacy and safety incompletely character...
M. Amjad, Muhammad Mustafa Khan, Fatima Sarwar et al.· Diabetes, obesity and metabo...· 0 citations
Left atrial appendage closure (LAAC) has emerged as an alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation (AF), particularly among individuals at increased risk of bleeding. We performed an updated systematic review and meta-analysis of randomized controlled trials comp...
Faiq Farooq, Syeda Irza Fatima, Muhammad Maaz Amjad et al.· Critical Pathways in Cardiol...· 0 citations
BackgroundTriple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options. Platinum agents, particularly carboplatin's DNA damaging properties suggest efficacy, its impact on survival outcomes and toxicity remains uncertain.MethodsPubMed, Embase, Scopus, Cochrane Library, and Clini...
M. Amjad, M. Bashir, Khwaja Waleed Maqbool et al.· Journal of Oncology Pharmacy...· 0 citations
OBJECTIVES
Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate delivering SN-38, has shown promising activity in advanced breast cancer. However, variability across trials and inclusion of nonrandomized data in prior meta-analyses limit the certainty of its efficacy and safety. This study aimed to eva...
M. Amjad, M. Rafique, S. F. Hussain et al.· American Journal of Clinical...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.